Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b-2 Study of Entospletinib With Vincristine in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
2015-002731-17Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entospletinib in mature B-cell lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by Gilead Sciences. Primary endpoint: Dose-limiting toxicities of entospletinib + vincristine. Started Nov 2015; status: completed.
02
Drugs
entospletinib
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2015-002731-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002731-17.